# ImmuPharma PLC LupuzorT Pivotal Phase III Study On Track and On Time

- Link: https://www.directorstalkinterviews.com/immupharma-plc-lupuzort-pivotal-phase-iii-study-track-time/412739111
- Published: 2017-11-02T07:22:46+00:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company,
has today provided an update of its pivotal 52-week, randomised, double-blinded,
Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough
compound for Lupus, the life threatening auto-immune disease.

· Study summary as at 1st November 2017

· 200 patients successfully recruited and randomised (dosed)

o all patients in the study have now passed the 9 months stage

o 116 of patients (58%) have completed the full 12 months of the study

· Continued robust safety record which remains consistent with Lupuzor™’s product
profile as shown in its previous Phase IIb study

· Top line results remain on track to be reported in Q1 2018

> **Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma Plc said:**“
> The trial continues to progress on track and on time, with all patients in the
> study now having passed the 9 month stage and 116 patients (58%) having completed
> the full 12 months.
> “Most importantly, we continue to see robust safety within the study which is 
> as equally important as the efficacy profile, in order for Lupuzor™ to be proactively
> prescribed by specialists to Lupus patients, who urgently require a more effective
> treatment for their condition.
> “We look forward with confidence to reporting top line results of the study in
> Q1 2018.”

Share on: